Anti-BCMA and GPRC5D bispecific antibodies in relapsed/refractory primary plasma cell leukemia: a case report

Anti-BCMA and GPRC5D bispecific antibodies in relapsed/refractory primary plasma cell leukemia: a case report

Plasma cell leukemia (PCL) is an aggressive and high-risk variant of multiple myeloma (MM) with a very poor prognosis. Given its rarity and aggressiveness, there is a lack of clinical trials testing the efficacity of novel therapies in these patients. New immune approaches such as B-cell maturation...

Full description

Bibliographic Details
Main Authors: Chiara Bernardi, Yan Beauverd, Thien An Tran, Marie Maulini, Maria Mappoura, Sarah Morin, Federico Simonetta, Anne Cairoli, Holger W. Auner, Kaveh Samii, Yves Chalandon, Carmen de Ramon Ortiz
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-11-01
Series:Frontiers in Immunology
Subjects:
bispecific Ab
plasma cell leukemia (PCL)
BCMA
GPRC5D
elranatamab
talquetamab
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1495233/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1495233/full

Similar Items